First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.

José Manuel Pérez García,Javier Cortes,Anastasios Stathis,Rogier Mous,Elena López-Miranda,A. Azaro,Sofia Genta,Paolo Nuciforo,Ana Vivancos,Renata Ferrarotto,Francesco Bertoni,Davide Rossi,Nicole Spardy Burr,Oliver Schönborn-Kellenberger,Karin Jorga,Laura Beni,Rajwinder Lehal,Michael Bauer,Dirk Weber,Elena Garralda

First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.

2018

TPS2619Background: NOTCH signalling is a key development pathway whose aberrant activation is recognised to play an oncogenic role in human cancers. When NOTCH signalling is inappropriately activat...

Keywords:

Notch signaling pathway
Protein–protein interaction
Pathology
Cancer research
Medicine
first in human

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations